NI201800063A - Compuesto de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer - Google Patents

Compuesto de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Info

Publication number
NI201800063A
NI201800063A NI201800063A NI201800063A NI201800063A NI 201800063 A NI201800063 A NI 201800063A NI 201800063 A NI201800063 A NI 201800063A NI 201800063 A NI201800063 A NI 201800063A NI 201800063 A NI201800063 A NI 201800063A
Authority
NI
Nicaragua
Prior art keywords
compound
thadiazole
cancer
treatment
formula
Prior art date
Application number
NI201800063A
Other languages
English (en)
Inventor
Raymond Verschoyle Finlay Maurice
Robert Perkins David
Wilhelmus Maria Nissink Johannes
Antoni Raubo Piotr
Duncan Smith Peter
Bailey Andrew
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201800063A publication Critical patent/NI201800063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo, se describe. Q puede ser, piridazin-3-ilo , 6- fluoropiridazin-3-ilo ; R1 puede ser H; R2 y R3 pueden ser independientemente alquilo C1-C6, o R2 y R3 tomados juntos son (CH 2)3- ; o R1 y R2 tomados juntos pueden ser - (CH2)2- y R3 pueden ser -CH3 ; R4 halo, -CH3, -OCH3 , -OCHF2 , -OCF3, o -CN; y n puede ser 0, 1, o 2. El compuesto de fórmula (I) puede inhibir la glutaminasa, por ejemplo, GLS1.
NI201800063A 2015-11-30 2018-05-29 Compuesto de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer NI201800063A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30

Publications (1)

Publication Number Publication Date
NI201800063A true NI201800063A (es) 2018-10-18

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800063A NI201800063A (es) 2015-11-30 2018-05-29 Compuesto de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Country Status (28)

Country Link
US (1) US10040789B2 (es)
EP (1) EP3383872B1 (es)
JP (1) JP6821680B2 (es)
KR (1) KR20180083411A (es)
CN (1) CN108349965B (es)
AR (1) AR106875A1 (es)
AU (1) AU2016361834B2 (es)
BR (1) BR112018008330B1 (es)
CA (1) CA3005517C (es)
CL (1) CL2018001409A1 (es)
CO (1) CO2018006930A2 (es)
DK (1) DK3383872T3 (es)
DO (1) DOP2018000135A (es)
EA (1) EA035519B9 (es)
ES (1) ES2796562T3 (es)
IL (1) IL259508A (es)
MX (1) MX2018006483A (es)
MY (1) MY195680A (es)
NI (1) NI201800063A (es)
NZ (1) NZ743699A (es)
PE (1) PE20181522A1 (es)
PH (1) PH12018501133A1 (es)
SG (1) SG11201803808VA (es)
SV (1) SV2018005700A (es)
TN (1) TN2018000118A1 (es)
TW (1) TW201731511A (es)
WO (1) WO2017093301A1 (es)
ZA (1) ZA201804361B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201730188A (zh) 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
JP7026852B2 (ja) * 2018-10-16 2022-02-28 メッドシャイン ディスカバリー インコーポレイテッド チアジアゾール誘導体及びｇｌｓ１阻害剤としてのその使用
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2782570T (lt) * 2011-11-21 2020-01-10 Calithera Biosciences Inc. Gliutaminazės heterocikliniai inhibitoriai
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EA035499B1 (ru) 2014-01-06 2020-06-25 Ризен Фармасьютикалз Са Новые ингибиторы глутаминазы
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
CA3005517A1 (en) 2017-06-08
PE20181522A1 (es) 2018-09-24
CA3005517C (en) 2023-12-12
US10040789B2 (en) 2018-08-07
DOP2018000135A (es) 2018-06-30
KR20180083411A (ko) 2018-07-20
CN108349965A (zh) 2018-07-31
PH12018501133A1 (en) 2019-01-21
BR112018008330A2 (pt) 2018-10-30
SV2018005700A (es) 2019-03-07
JP2018535235A (ja) 2018-11-29
CO2018006930A2 (es) 2018-10-10
EA035519B1 (ru) 2020-06-29
EA201891239A1 (ru) 2018-11-30
ES2796562T3 (es) 2020-11-27
AU2016361834A1 (en) 2018-07-12
US20170333429A1 (en) 2017-11-23
JP6821680B2 (ja) 2021-01-27
BR112018008330B1 (pt) 2023-03-07
EP3383872B1 (en) 2020-05-20
EP3383872A1 (en) 2018-10-10
NZ743699A (en) 2023-02-24
CN108349965B (zh) 2021-10-26
DK3383872T3 (da) 2020-06-08
SG11201803808VA (en) 2018-06-28
MX2018006483A (es) 2019-08-12
AR106875A1 (es) 2018-02-28
CL2018001409A1 (es) 2018-12-07
MY195680A (en) 2023-02-03
EA035519B9 (ru) 2020-08-10
TN2018000118A1 (en) 2019-10-04
TW201731511A (zh) 2017-09-16
AU2016361834B2 (en) 2019-11-14
IL259508A (en) 2018-07-31
ZA201804361B (en) 2019-07-31
WO2017093301A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
NI201800063A (es) Compuesto de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR094553A1 (es) Formas de oxadiazolpirazina
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
PE20171335A1 (es) Inhibidores de gingipaina de lisina
MX2021001612A (es) Compuestos utiles en terapia del vih.
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
CL2020000553A1 (es) Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso.
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer